Perioperative Outcomes of Transurethral Resection, Open Prostatectomy, and Laser Therapy in the Surgical Treatment of Benign Prostatic Obstruction: A "Real-World" Data Analysis from the URO-Cert Prostate Centers.


Journal

Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373

Informations de publication

Date de publication:
2021
Historique:
received: 20 12 2020
accepted: 16 03 2021
pubmed: 22 7 2021
medline: 19 1 2022
entrez: 21 7 2021
Statut: ppublish

Résumé

The aim of the study is to compare length of hospital stay, transfusion rates, and re-intervention rates during hospitalization for transurethral resection of the prostate (TUR-P), open prostatectomy (OP), and laser therapy (LT) for surgical treatment of benign prostatic obstruction (BPO). URO-Cert is an organization, in which clinical data of prostatic diseases from 2 university, 19 public, and 3 private hospitals and 270 office-based urologists are collected in order to document treatment quality. Data on diagnostics, therapy, and course of disease are recorded web based. The analysis includes datasets from 2005 to 2017. Of 10,420 patients, 8,389 were treated with TUR-P, 1,334 with OP, and 697 with LT. Median length of hospital stay was 6 days (IQR: 4-7) for TUR-P, 9 days (IQR: 7-11) for OP, and 5 days (IQR: 4-6) for LT (p < 0.001). Risk for a hospital stay ≥7 days was higher for OP versus TUR-P (OR: 7.25; 95% CI = 6.27-8.36; p < 0.001) and LT (OR: 17.89; 95% CI = 14.12-22.65; p < 0.001) and higher for TUR-P versus LT (OR: 2.47; 95% CI = 2.03-3.01; p < 0.001). OP had a significantly higher risk for transfusions than TUR-P (OR: 2.44; 95% CI = 1.74-3.41; p < 0.001) and LT (OR: 3.32; 95% CI = 1.56-7.01; p < 0.001). Transfusion rates were not significantly different between TUR-P and LT (OR: 1.36; 95% CI = 0.66-2.79; p = 0.51). Risk of re-intervention was not different between all 3 approaches. OP was associated with higher transfusion rates and longer hospital stay than TUR-P and LT. Risk of transfusion was not different between TUR-P and LT, but TUR-P was inferior to LT concerning length of hospital stay. Re-intervention rates during hospitalization did not differ between the groups.

Identifiants

pubmed: 34289488
pii: 000517673
doi: 10.1159/000517673
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

869-874

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Jan Herden (J)

URO-Cert, Berlin, Germany.
Prostatecenter Cologne, Cologne, Germany.

Thomas Ebert (T)

Prostatecenter Metropolregion Nuremberg, Fuerth, Germany.

Daniel Schlager (D)

Prostatecenter Freiburg, Freiburg, Germany.

Jana Pretzer (J)

Prostatecenter Berlin, Berlin, Germany.

Daniel Porres (D)

Prostatecenter Leverkusen, Leverkusen, Germany.

Wolfgang Schafhauser (W)

Prostatecenter Hochfranken-Fichtelgebirge, Marktredwitz, Germany.

Martin Kriegmair (M)

Urology Center Munich, Planegg, Germany.

Miguel Garcia Schürmann (MG)

Prostatecenter Niederrhein, Wesel, Germany.

Florian Distler (F)

Prostatecenter Nuremberg-Middle Franconia, Nuremberg, Germany.

Frank Oberpenning (F)

Prostatecenter Bocholt, Bocholt, Germany.

Michael Reimann (M)

Prostatecenter Moers, Moers, Germany.

Gerald Haupt (G)

Prostatecenter Speyer, Speyer, Germany.

Sebastian Schmidt (S)

Prostatecenter Rhine-Ruhr, Oberhausen, Germany.

Sven Laabs (S)

Prostatecenter Elbe-Weser, Stade, Germany.

Bernhard Planz (B)

Prostatecenter Emscher-Lippe, Gladbeck, Germany.

Maximilian Cohausz (M)

Prostatecenter Muensterland, Muenster, Germany.

Eckart Gronau (E)

Prostatecenter Muensterland, Muenster, Germany.

Guido Platz (G)

Prostatecenter Mainspitze, Ruesselsheim, Germany.

Stephan Buse (S)

Prostatecenter Alfred Krupp-Hospital, Essen, Germany.

Jon Jones (J)

Prostatecenter Hochtaunus, Bad Homburg, Germany.

Michael Waldner (M)

Prostatecenter Cologne, Cologne, Germany.

Axel Heidenreich (A)

Prostatecenter Cologne, Cologne, Germany.

Herbert Ruebben (H)

URO-Cert, Berlin, Germany.

Juergen Zumbe (J)

URO-Cert, Berlin, Germany.

Alexander Goell (A)

URO-Cert, Berlin, Germany.

Ehsan Khaljani (E)

URO-Cert, Berlin, Germany.

Winfried Czempiel (W)

URO-Cert, Berlin, Germany.

Wolfgang Schultze-Seemann (W)

URO-Cert, Berlin, Germany.
Prostatecenter Freiburg, Freiburg, Germany.

Peter Weib (P)

URO-Cert, Berlin, Germany.
Prostatecenter Siegen, Siegen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH